Group 1 - Recordati's subsidiary in China, Ruikangdi, has officially exited the Chinese market, ceasing the supply of three rare disease drugs, which may disrupt treatment for patients [1][2] - The drug with the most significant impact from the exit is the innovative drug Shireza, which has no domestic generic alternatives, potentially leaving Cushing's syndrome patients without medication [1][2] - Approximately 40,000 to 50,000 patients in China suffer from Cushing's syndrome, with only about 3,000 requiring drug treatment [1] Group 2 - Ruikangdi, a small enterprise focused on rare diseases, is a subsidiary of Recordati, which operates in around 150 countries and has been involved in the rare disease sector since 1990 [2] - The direct reason for the market exit was a failure in health insurance negotiations, as two of its drugs did not make it into the 2025 health insurance directory [2] - The challenges faced by rare disease drug companies in China include high investment costs with low returns, as the development cost for a single orphan drug is approximately 260 million yuan, while the rare disease drug market in China accounts for only 3% of the global market [3] Group 3 - The Chinese rare disease patient population exceeds 20 million, with over 200,000 new patients added each year [3] - The industry is facing insufficient health insurance coverage, with 83% of rare disease drugs having annual treatment costs exceeding 300,000 yuan, and only 50% being included in health insurance [3] - Policy initiatives are being explored to address these challenges, such as the Boao Lecheng Pilot Zone allowing expedited approval for unapproved drugs and encouraging local innovation in the rare disease sector [3]

新京报讯(记者王卡拉)4月12日，磷酸奥唑司他片(商品名：适锐飒)正式在中国商业化上市，成为国内目 前唯一获批用于治疗成人库欣综合征(皮质醇增多症)的口服新药，填补了该罕见病国内药物治疗的空 白。 磷酸奥唑司他片是Recordati集团中国全资子公司锐康迪(北京)医药有限公司旗下的First-in-Class新药(首 创新药)，在美国、欧盟、澳大利亚得到孤儿药认定，并且作为"临床急需的短缺药品、防治重大传染病 和罕见病等疾病的创新药和改良型新药"于2023年9月获国家药监局药品审评中心优先审评审批资格，并 在2024年9月正式获得国家药监局的进口批文，此次是正式商业化上市。 全球多项临床研究的积极结果已充分验证了磷酸奥唑司他片的有效性和安全性。北京大学第一医院内分 泌科郭晓蕙教授分享的两项覆盖全球210例患者的三期临床研究显示，磷酸奥唑司他片可以快速且持久 地降低皮质醇水平，最长维持疗效超4年，生活质量显著改善，且中国患者对磷酸奥唑司他片更加敏 感，每日用量大概只有欧美患者的一半。 "手术依然是库欣综合征的一线治疗方法，但新药的加入正在拓展全新治疗格局。"北京天坛医院神经外 科刘丕楠教授认为，磷酸奥唑司他片可 ...